CANVAS - CANagliflozin cardioVascular Assessment Study
Public ClinicalTrials.gov record NCT01032629. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE). Other objectives include evaluating the overall safety, tolerability, and effectiveness of canagliflozin. The data from this study will be combined with the data from CANVAS-R study (Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects with T2DM, NCT01989754) in a pre-specified integrated analysis of CV safety outcomes to satisfy US FDA post-marketing requirements for canagliflozin.
Study identification
- NCT ID
- NCT01032629
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 4,330 participants
Conditions and interventions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 9, 2009 (Actual)
- Primary completion
- Feb 22, 2017 (Actual)
- Completion
- Feb 22, 2017 (Actual)
- Last update posted
- Dec 7, 2018
2009 – 2017
United States locations
- U.S. sites
- 58
- U.S. states
- 25
- U.S. cities
- 58
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Mesa | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | La Mesa | California | — | — |
| Not listed | Los Gatos | California | — | — |
| Not listed | Pismo Beach | California | — | — |
| Not listed | Stockton | California | — | — |
| Not listed | Walnut Creek | California | — | — |
| Not listed | Doral | Florida | — | — |
| Not listed | Fort Lauderdale | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Plantation | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Duluth | Georgia | — | — |
| Not listed | Boise | Idaho | — | — |
| Not listed | Eagle | Idaho | — | — |
| Not listed | Meridian | Idaho | — | — |
| Not listed | Peoria | Illinois | — | — |
| Not listed | Topeka | Kansas | — | — |
| Not listed | Crestview Hills | Kentucky | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Auburn | Maine | — | — |
| Not listed | Scarborough | Maine | — | — |
| Not listed | Oxon Hill | Maryland | — | — |
| Not listed | Royal Oak | Michigan | — | — |
| Not listed | Kansas City | Missouri | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Camden | New Jersey | — | — |
| Not listed | Flushing | New York | — | — |
| Not listed | The Bronx | New York | — | — |
| Not listed | Chapel Hill | North Carolina | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | Gallipolis | Ohio | — | — |
| Not listed | Mentor | Ohio | — | — |
| Not listed | Toledo | Ohio | — | — |
| Not listed | Beaver | Pennsylvania | — | — |
| Not listed | Norristown | Pennsylvania | — | — |
| Not listed | Sayre | Pennsylvania | — | — |
| Not listed | Greenville | South Carolina | — | — |
| Not listed | Kingsport | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Odessa | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Temple | Texas | — | — |
| Not listed | Draper | Utah | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Sandy City | Utah | — | — |
| Not listed | West Jordan | Utah | — | — |
| Not listed | Danville | Virginia | — | — |
| Not listed | Richmond | Virginia | — | — |
| Not listed | Spokane | Washington | — | — |
| Not listed | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 247 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01032629, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 7, 2018 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01032629 live on ClinicalTrials.gov.